And you, Galzus Research, keep proving that someone, some outfit, is paying you..
Here is why...
When an author writes an investigational report, It is usually based on skillful/unbiased interpretation of the data, It is peer REVIEWED, and the said Author sign it Very Proudly & Confidently, WITHOUT APPARENT FEAR, by Putting His/her Name on it...
As you might have NOTICED, Your Work is a "NOONE, NONAME WORK"..!!!!
Beside that, the said Morally Responsible Author doesn't spend 24/7 on the MB, where the paper is written about, TRYING TO CONVINCE INVESTORS/READERS that he is Absolutely correct (over & over & over again) about his OPINION (as yours is just that) that the technology/company he has written about not worth considering as an investment option!!
And your response in the post below "Why would Novocure be afraid of a treatment that absolutely is not getting approved in the US, because the company hasn't bothered to file" shows how NAIVE YOU ARE in your assessment as, If you have not also NOTICED, we live in a Global Society & Approval Anywhere WILL negatively Impacting competing therapeutic Contenders/Pretenders..!!
Lastly, you might be correct that Novocure has not directly paid you, but in my opinion, other Parties with vest interest might have....
Take care & keep pushing your Opinion piece!!
P.S. I MIGHT HAVE HIT THE NAIL ON THE HAED AS YOU CALLED ME THIS .... "You are about the dullest tack in the drawer, it would seem"
Again, take care & good luck.. !!
.
But Should rember, You Have Been Calling WOLF too many times!!
Here is why...
When an author writes an investigational report, It is usually based on skillful/unbiased interpretation of the data, It is peer REVIEWED, and the said Author sign it Very Proudly & Confidently, WITHOUT APPARENT FEAR, by Putting His/her Name on it...
As you might have NOTICED, Your Work is a "NOONE, NONAME WORK"..!!!!
Beside that, the said Morally Responsible Author doesn't spend 24/7 on the MB, where the paper is written about, TRYING TO CONVINCE INVESTORS/READERS that he is Absolutely correct (over & over & over again) about his OPINION (as yours is just that) that the technology/company he has written about not worth considering as an investment option!!
And your response in the post below "Why would Novocure be afraid of a treatment that absolutely is not getting approved in the US, because the company hasn't bothered to file" shows how NAIVE YOU ARE in your assessment as, If you have not also NOTICED, we live in a Global Society & Approval Anywhere WILL negatively Impacting competing therapeutic Contenders/Pretenders..!!
Lastly, you might be correct that Novocure has not directly paid you, but in my opinion, other Parties with vest interest might have....
Take care & keep pushing your Opinion piece!!
P.S. I MIGHT HAVE HIT THE NAIL ON THE HAED AS YOU CALLED ME THIS .... "You are about the dullest tack in the drawer, it would seem"
Again, take care & good luck.. !!
.
But Should rember, You Have Been Calling WOLF too many times!!
Recent NVCR News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/21/2026 08:00:26 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/08/2026 09:01:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 11:01:40 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/30/2026 11:01:01 AM
- Novocure Reports First Quarter 2026 Financial Results • Business Wire • 04/30/2026 11:00:00 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 04/24/2026 08:08:39 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/20/2026 08:06:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/20/2026 08:05:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 09:04:13 PM
- Novocure to Report First Quarter 2026 Financial Results • Business Wire • 04/01/2026 11:00:00 AM
- Novocure shares gain on encouraging pancreatic cancer trial results • IH Market News • 03/26/2026 02:24:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 11:00:57 AM
- Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer • Business Wire • 03/26/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:33:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:32:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:32:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:31:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:31:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:31:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:31:04 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2026 09:06:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:54:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:53:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:42:44 PM
